Investment Thesis — Baxter International Inc.
The market is overly focused on Baxter's recent negative EPS and the implied dividend uncertainty, overlooking the significant value creation potential from its planned strategic portfolio optimization. The current valuation implies a permanent impairment, while a successful spin-off could unlock distinct, higher multiples for its diversified healthcare segments.
Catalysts
- Successful execution and completion of the Renal Care and Acute Therapies spin-off.
- Clear communication of a sustainable dividend policy post-spin-off, removing uncertainty.
- Evidence of operational improvements and a return to positive, growing EPS in the core MedTech business.
Risk Factors
- Failure or significant delay in the planned spin-off, prolonging uncertainty and debt burden.
- Deterioration of core business performance or unexpected regulatory hurdles.
- A deeper-than-expected dividend cut or suspension, leading to a significant investor exodus.
Key Debates
Net Margin turns positive by Q2 2025 from restructuring
D/E ratio falls below 1.20 by Q3 2025 via asset sales
P/S multiple expands above 1.0x by Q1 2025 on growth